Primary Endpoints

Filana Therapeutics

25/11/2024 12:42

Nov 25 (Reuters) - Cassava Sciences Inc  SAVA.O :
    * CASSAVA SCIENCES TOPLINE PHASE 3 DATA DID NOT MEET
CO-PRIMARY
ENDPOINTS
    * CASSAVA SCIENCES INC: SIMUFILAM CONTINUED TO DEMONSTRATE
AN
OVERALL FAVORABLE SAFETY PROFILE
    * CASSAVA SCIENCES INC: SIMUFILAM DID NOT SHOW A SIGNIFICANT
REDUCTION IN COGNITIVE OR FUNCTIONAL DECLINE VERSUS PLACEBO
    * CASSAVA SCIENCES INC: ALSO BE DISCONTINUING OPEN LABEL
EXTENSION
STUDY
    * CASSAVA SCIENCES INC: TO DISCONTINUE REFOCUS-ALZ

Source text:  ID:nGNX2dkZqJ 
Further company coverage:  SAVA.O 

 ((Reuters.Briefs@thomsonreuters.com;))